The quest for generic biotechnology pharmaceuticals in the USA

Kowalski, Thomas J.; Fekete, Pamela; Yvon, Anne-Marie C.
April 2005
Journal of Commercial Biotechnology;Apr2005, Vol. 11 Issue 3, p271
Academic Journal
As patent protection expires on the first generation of biotechnology products, such as human growth hormone and erythropoietin, there is an impetus for the development and marketing of generic equivalents. Currently there is no statutory or regulatory framework governing generic biotechnology products. This paper explores the potential solutions that have been suggested by members of the pharmaceutical industry and government, both in the USA and internationally.


Related Articles

  • After years of peaks, 'patent cliff' to slow generics growth. DeArment, Alaric // Drug Store News;11/17/2008, Vol. 30 Issue 14, p46 

    The article reports on the impact of the decline of the supply of expiring patents on the generic drug companies in the U.S. It is said that generic drug companies will have to adapt as market becomes increasing commoditized. According to IMS vice president of industry relations Doug Long,...

  • News in brief….  // PharmacoEconomics & Outcomes News;12/3/2005, Issue 492, p11 

    The article presents information on a study conducted in The Netherlands which examined the effect of drug patent expiry for enalapril on the sale of generic drugs. The researchers found that after the patent expiry, the sale of generic drugs in the country increased.

  • Under Review.  // Pharmaceutical Executive;May2002, Vol. 22 Issue 5, p142 

    Highlights several issues critical to the pharmaceutical industry that need to be addressed. Need to balance companies' intellectual property rights with patients' right to access lower-priced generics; Pharmacovigilance and fast-track registration; Biotechnology issues.

  • Privatising life. Fraser, Hugh // UNESCO Sources;Nov99, Issue 117, p7 

    Focuses on the issue concerning companies' claim to areas of human life through patent grants in the United States. Firms' ownership of patents; Difference between invention and finding; Intellectual property; Government efforts to prevent private companies from owning patents on human genes. ...

  • The production of generic drugs in India: Would be affected by new trade agreement with EU. Love, James // BMJ: British Medical Journal (International Edition);4/2/2011, Vol. 342 Issue 7800, p721 

    The author reflects on the trade agreement negotiated between European Union (EU) and India which may affect the production of generic drugs. The author says that the deal, which restricts ownership and enforcement of intellectual property for medical inventions, if implemented, may shrink the...

  • Patent Challenges. J. W. // Pharmaceutical Executive;Jun2007, Vol. 27 Issue 6, p24 

    The article reports that Thailand Government and other third-world nations are challenging patents on critical therapies, a tactic that is stepping up into a serious international confrontation over intellectual property protection. Thailand has been trying to override drug patents on AIDS...

  • Ethical Pharma Companies Fight Generics Head On. Scott, Alex // Chemical Week;7/5/2006, Vol. 168 Issue 23, p22 

    This article reveals that some ethical pharmaceutical companies have started to challenge the established pricing model for branded pharmaceuticals that go off patent. Merck and Pfizer have each opted to offer major price discounts on leading drugs that recently went off patent, to fight...

  • Litigation Is The Business Model For Generic Drug Maker. Andersen, Steven // Corporate Legal Times;Apr2003, Vol. 13 Issue 137, p24 

    Presents a discussion on the litigation challenges faced by Teva Pharmaceutical Industries Limited, manufacturer of generic drugs, in the U.S. Difficulty of handling international intellectual property function; Description of patents held; Competition with brand name pharmaceutical companies. ...

  • Tick-tock stop the clock Generics and extended patent protection. Wynne, Clarissa // Chemistry in Australia;Dec2010, Vol. 78 Issue 11, p7 

    The article discusses various ways in which the owner of the original compound can extend patent rights beyond the 20-year term of a patent to the original compound and prevent generic competition. The owner can apply for an extension of terms of up to five years. To extend the period of market...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics